29 June 2021 in Siberian journal of oncology
Purpose: to conduct a preliminary analysis of the safety and effectiveness of hifu-therapy with a lowenergy hifu-2001 device (shenzhen Huikang Medical apparatus Co., ltd) performed concurrently with chemotherapy in pancreatic cancer patients who are not suitable for surgery or chemoradiotherapy.Material and Method. The study included 24 pancreatic cancer patients who were treated at the Hertsen Moscow Oncology Research institute in the period from 2016 to 2019. There were 17 (71 %) women and 7 (29 %) men. The percentage of patients in the elderly group was 79 %. Stage iia pancreatic cancer was diagnosed in 3 (12.5 %) patients, stage ii in 5 (21 %) patients, stage iii in 9 (37.5 %) patients, and stage iv in 7 (29 %) patients. All patients received combination therapy, including systemic chemotherapy and hifu-therapy. Results. The most frequent adverse events of treatment were skin burns (n=6), with third-degree burns occurring in 2 (8.3 %) patients. Local sclerosis of subcutaneous adipose tissue was observed in 4 (17 %) patients; development of asymptomatic pancreatic pseudocysts in the area of hifu exposure was observed in 1 (4 %) patient. Pain control was achieved in 17 (85 %) patients, and local tumor control was achieved in 19 (79.2 %) patients. The follow-up time ranged from 5 to 30 months with a median time of 14.5 months. The median total life expectancy of patients was 16 months, and the median time to progression was 9 months. The overall 6-month survival rate was 100 %. The 1- and 1.5-year survival rates were 75.0 % and 41.7 %, respectively. The 2-year survival rate was 17.2 %. The 6-month and 1-year disease-free survival rates were 62.5 % and 12.5 %, respectively. Conclusion. The short- and long-term outcomes were consistent with those described in other studies, which indicated that a combination of systemic drug therapy and hifu-therapy is an appropriate approach for the treatment of patients with pancreatic cancer.
23 April 2024 in P.A. Herzen Journal of Oncology
Objective. Analysis of the results of treatment of patients with metastatic liver tumors using laser ablation. Material and methods. Results of treatment of 27 patients with metastatic liver lesions who underwent laser ablation for the period from March, 2017 to January 2023, were analyzed. The size of lesions was 10—40 mm, average size — 29.8±1.7 mm). Laser destruction was performed percutaneously, with laparoscopic and open approaches under ultrasound scanning in real time mode. For laser ablation, an ECHO LASER X4 device (Italy) was used. Ultrasound, MRI and CT with intravenous contrast were used for the dynamically control of ablation effectiveness. Results. In the early postoperative period, in one case, the formation of a subcapsular hematoma was observed in the area of the light guide, which did not require surgical intervention. The average bed/day was 4 days. One-year overall survival stood at 88%, two-year overall survival stood at 71%, 3-years — 43.5%. Conclusion. The use of laser ablation is indicated for insufficient functional liver volume in patients with previously extensive liver resections, and in somatically burdened patients who cannot undergo liver resection.
1 January 2021 in P.A. Herzen Journal of Oncology
Представлено клиническое наблюдение холангиоцеллюлярного рака печени с вовлечением печеночных вен и нижней полой вены. Использование двух высокотехнологичных методик эндоваскулярной химиоэмболизации и расширенной экстракорпоральной резекции печени с резекцией и пластикой нижней полой вены позволили выполнить R0-резекцию, дающую надежду на благоприятный прогноз в плане отдаленных результатов.
7 August 2021 in Meditsinskiy sovet = Medical Council
Introduction. The gold standard for the treatment of patients with a localized form of pancreatic cancer is radical surgical intervention. It is characterized by a high frequency of postoperative complications and is not performed in patients with a weakened general functional status and the presence of multiple severe concomitant somatic pathology.Purpose. The aim of this study is a assessment of the safety and effectiveness of combined treatment with the inclusion of gemcitabine chemotherapy and HIFU therapy in somatically inoperable patients with localized pancreatic adenocarcinoma of the elderly and senile age.Materials and methods. This study involved 15 patients with stage II (T3N0-1M0) disease aged 60 years and older, with a performance status ECOG 2 and a high operational and anesthetic risk, who received palliative combined treatment on the basis of the P. Hertsen Moscow Oncology Research Institute in the period from 2017 to 2020. HIFU therapy was performed on the HIFU2001 (Shenzhen Huikang Medical Apparatus Co., Ltd.), local treatment sessions were carried out in the amount of 3–8 per course, conducted daily, in the intervals between days of intravenous administration of gemcitabine at a dosage of 1000 mg/m2 (1, 8, 15 days every 4 weeks).Results. Adverse events of systemic drug therapy were observed in 9 (60%) patients, local complications of HIFU therapy — in 6 (37.5%) patients. 6 months after the start of treatment, pain control was achieved in 87.5% of patients, local progression of the disease was detected in 2 (13.3%) cases, and a partial tumor response was determined in 2 patients and stable disease in 11 patients. The median overall survival was 19 months, and the median progression-free survival was 12 months. The overall 1-, 2-, and 3-year survival rate was 80%, 20%, and 13%, respectively, and the 1-year progression-free survival rate was 54%.Conclusions. The results of this study demonstrate the prospects of using a combination of HIFU therapy and gemcitabine monotherapy in somatically inoperable patients with localized pancreatic adenocarcinoma of the elderly and senile age.
27 June 2023 in P.A. Herzen Journal of Oncology
This communication deals with a complex and not fully resolved problem, which option of surgical treatment is more preferable for liver tumors of central localization, extended hemihepatectomy or median resection. It should be noted that the most aggressive approach to the parenchymal-sparing variant with the formation of biliodigestive anastomoses and preservation of the portal inflow to segment VII by imposing a venous portal anastomosis is presented in the clinical case. There are data from the largest publications, including meta-analyses, which compare the results of these operations in patients with hepatocellular carcinoma, with metastases of colorectal cancer and intrahepatic cholangiocarcinoma.
3 August 2023 in P.A. Herzen Journal of Oncology
Colorectal cancer (CRC) is diagnosed as a metastatic disease in most (about 60%) patients. The overall 5-year survival rate for CRC patients is 40-60%, which makes it necessary to look for new systemic and regional treatments for this disease and to improve its traditional ones. The paper describes two rare clinical cases of CRC metastasis to the left supraclavicular lymph nodes.